Bloomberg News

Albany Molecular Tumbles as Bristol-Myers Ends Drug Studies (1)

August 12, 2013

Albany Molecular Research Inc. (AMRI:US) fell the most in three months after saying that Bristol-Myers Squibb Co. (BMY:US) ended development of a depression drug under partnership.

Albany Molecular declined 10 percent to $11.31 at the close in New York, the biggest single-day drop since May 7. Shares of the Albany, New York-based company have more than doubled this year.

Bristol-Myers is ending testing on BMS-820836, an experimental depression treatment, after the medicine failed to meet its goals in clinical studies, Albany Molecular said today in a regulatory filing. The two companies will have “continued discussions” about the compound’s future and plans for other medicines, according to the filing.

Albany Molecular said the end of the drug’s development wouldn’t affect the forecast for the 2013 third-quarter and full year. The company said Aug. 6 that it expects (AMRI:US) earnings excluding some items of 9 cents to 12 cents a share for the quarter and 54 cents to 65 cents for the year.

To contact the reporter on this story: Alex Nussbaum in New York at anussbaum1@bloomberg.net

To contact the editor responsible for this story: Reg Gale at rgale5@bloomberg.net


Hollywood Goes YouTube
LIMITED-TIME OFFER SUBSCRIBE NOW

(enter your email)
(enter up to 5 email addresses, separated by commas)

Max 250 characters

Companies Mentioned

  • AMRI
    (Albany Molecular Research Inc)
    • $19.8 USD
    • -0.01
    • -0.05%
  • BMY
    (Bristol-Myers Squibb Co)
    • $50.65 USD
    • 0.11
    • 0.22%
Market data is delayed at least 15 minutes.
 
blog comments powered by Disqus